INCR: מכפיל P/S עתידי InterCure Ltd
InterCure Ltd. (INCR) minimizes regional risks by diversifying sales between Europe and Israel. The forward P/S valuation history demonstrates the dynamics of capitalization relative to future sales, where the 0.50 mark records this metric. High pharmacy standards and variety patents protect the business from competitors. Growth relies on exclusive contracts with European brands as part of its expansion.
פילוחי מדדים ואנליטיקה של חברת intercure.co (INCR)
InterCure Ltd. (INCR) status as a leading Israeli medical cannabis operator with exclusive market access makes the company's cash flows predictable. By analyzing the forward P/S based on forecasts, an investor assesses the ratio of current market capitalization to expected revenue, which helps determine the degree of asset undervaluation or the risk of acquiring a business with declining sales during periods of market volatility.
